First published 10/3/2026, 1:23:15 AM · Last updated 10/3/2026, 1:23:15 AM

MA03.02 Clinical Performance of a Tumor Informed Whole Genome Based ctDNA Assay for Predicting Recurrence in Early-Stage Resectable NSCLC

Article reports a clinical evaluation of a tumor-informed, whole-genome circulating tumor DNA assay intended to predict recurrence after resection of early-stage non-small cell lung cancer. The source is a journal article published by Elsevier BV with limited additional details in the provided excerpt.

Illustrative image: Scientists have discovered that dying tumor cells release small pieces of their DNA into the bloodstream. These pieces are called cell-free circulating tumor DNA (ctDNA). — Jonathan Bailey / NHGRI/Wikimedia Commons, CC BY-SA 4.0

Categories: science-and-space, public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 4/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 6/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

Results pertain to predicting recurrence in early-stage resectable NSCLC and could inform clinical decision-making.

Sources

MA03.02 Clinical Performance of a Tumor Informed Whole Genome Based ctDNA Assay for Predicting Recurrence in Early-Stage Resectable NSCLC

Report an issue